Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Collaboration extends global reach for Thermo Fisher’s rapid next-generation sequencing technology Conference call to be held today at 4:30 pm ET/1:30 pm PT IRVINE, Calif., Jan. 18, 2022 (GLOBE...
-
Data show DetermaCNI detects recurrence with higher sensitivity than standard of care biomarkers, high sensitivity with very low false positives DetermaCNI is the first clinical-grade test to monitor...
-
Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer DetermaIO...
-
IRVINE, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that...
-
IRVINE, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit ...
-
Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other...
-
DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has...
-
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant...
-
IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...